Article Figures & Data
Figures
- FIG 1.
Study design.
- FIG 2.
Comparison of nrCBV histogram parameters across each group of NER in the initial tumor. The mean, 90th percentile, and 95th percentile of the nrCBV values of the NER of the initial tumor were significantly higher in group MU than in group MM and group UU. Asterisks represent statistically significant differences among groups. 90P indicates the 90th percentile; 95P, the 95th percentile.
- FIG 3.
FLAIR images (A–C) and nrCBV maps (D–F) with corresponding cumulative histograms (G–I) for representative patients. A, D, G, A 34-year-old woman in group MM. B, E, H, A 37-year-old woman in group UU. C, F, I, A 32-year-old man in group MU. The histogram values (mean, 90th percentile, and 95th percentile) of the nrCBV in the NER of the tumors in group MU are higher than those in group UU or group MM.
Tables
Group MM (n = 13) Group UU (n = 18) Group MU (n = 9) Pb Age (yr) 49.9 (SD, 14.3) 51.6 (SD, 14.5) 46.3 (SD, 11.1) .61 Sex .52 Female 7 (53.8%) 10 (55.6%) 3 (33.3%) Male 6 (46.2%) 8 (44.4%) 6 (66.7%) IDH 1 or 2 mutation .06 Negative 9 (90.0%) 14 (100.0%) 6 (66.7%) Positive 1 (10.0%) 0 (0.0%) 3 (33.3%) EGFR amplification: initial tumor .85 Negative 7 (53.8%) 10 (55.6%) 4 (44.4%) Positive 6 (46.2%) 8 (44.4%) 5 (55.6%) EGFR amplification: recurrent tumor .81 Negative 8 (66.7%) 10 (55.6%) 5 (55.6%) Positive 4 (33.3%) 8 (44.4%) 4 (44.4%) WHO grade: initial tumor .12 Grade III anaplastic astrocytoma 1 (7.7%) 0 (0.0%) 2 (22.2%) Grade IV glioblastoma 12 (92.3%) 18 (100.0%) 7 (77.8%) WHO grade: recurrent tumor Grade IV 13 (100.0%) 18 (100.0%) 9 (100.0%) Surgical extent .32 Total resection 11 (84.62%) 11 (61.11%) 7 (77.78%) Subtotal resection 2 (15.4%) 0 (0.0%) 0 (0.0%) 1st preoperative KPS 100.0 (90.0–100.0) 92.5 (80.0–100.0) 100.0 (90.0–100.0) .41 2nd preoperative KPS 90.0 (80.0–100.0) 90.0 (70.0–100.0) 100.0 (90.0–100.0) .39 Postoperative treatment after 1st operation .42 CCRT/TMZ 11 (84.6%) 17 (94.5%) 8 (88.9%) Hypo-CCRT/TMZ 2 (15.4%) 0 (0.0%) 0 (0.0%) Hypo-CCRT 0 (0.0%) 1 (5.6%) 1 (11.1%) Radiation dose (Gy) 61.0 (61.0–61.0) 61.0 (61.0–61.0) 61.0 (61.0–61.0) .69 Note:—KPS indicates Karnofsky Performance Status.
↵a Data are number of patients, means [2 SDs] for normally distributed variables, or medians (interquartile ranges) for nonnormally distributed variables.
↵b P values were calculated using the Kruskal-Wallis test for nonparametric variables and the 1-way ANOVA for parametric variables.
- Table 2:
Diagnostic performance of the nrCBV values for discriminating unchanged MGMT methylation status (group MM) from changed MGMT methylation status (group MU) on the basis of the NER of the initial tumor
Variable AUC Sensitivity (%) Specificity (%) Cutoff Standard Error 95% CI P Initial tumor nrCBV mean 0.889 77.78 92.31 >2.594 0.073 0.682–0.982 <.0001 nrCBV 90P 0.846 88.89 76.92 >4.159 0.091 0.630–0.963 .0001 nrCBV 95P 0.855 66.67 92.31 >6.794 0.082 0.640–0.967 <.0001 Note:—90P indicates 90th percentile; 95P, 95th percentile; AUC, area under the curve.
